Andere Sprachen Oncopeptides AB

Aktien

A2DLU2

SE0009414576

ONCO

Markt geschlossen - Nasdaq Stockholm Andere Börsenplätze 17:29:54 15.04.2024			% 5 Tage	% 1. Jan.
5,23 ^SEK	+5,44 %		+0,97 %	-31,72 %

04.04.	Oncopeptides AB (Publ) gibt Umsatzprognose für das erste Quartal 2024 ab	CI
27.03.	Oncopeptides und Vector Pharma FZCO kündigen Zusammenarbeit an, um Patienten im Nahen Osten und Nordafrika mit Pepaxti zu versorgen	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Bulletin from an Extraordinary General Meeting in Oncopeptides AB (publ)	15.04.
Oncopeptides secures national reimbursement for Pepaxti in Spain	15.04.
Oncopeptides announces final terms for the fully guaranteed rights issue	08.04.
Oncopeptides releases first quarter 2024 sales	04.04.
Oncopeptides AB Provides Sales Guidance for the First Quarter of 2024	04.04.
Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa	27.03.
Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa	27.03.
Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa	27.03.
Extraordinary General Meeting in Oncopeptides AB (publ)	13.03.
Oncopeptides Plans SEK300 Million Rights Issue to Support Multiple Myeloma Drug Commercialization	13.03.
Oncopeptides : Oncopeptalks on the company's rights issue	13.03.
Oncopeptides carries out a fully guaranteed rights issue of approximately SEK 300 million to reach profitability during 2026	13.03.
FDA Flexes Its New FDORA Muscles In Withdrawing An Accelerated Approval	08.03.
Oncopeptides PORT study shows peripheral administration of Pepaxti being equally safe as central venous administration	04.03.
Oncopeptides : to present at two investor events	04.03.
Oncopeptides AB - Pepaxti provides sustained health related Quality of Life OCEAN study shows, article published in Haematologica	01.03.
Oncopeptides' : PORT study shows peripheral administration of Pepaxti being equally safe as central venous administration	01.03.
Oncopeptides’ PORT study shows peripheral administration of Pepaxti being equally safe as central venous administration	01.03.
Pepaxti provides sustained health related Quality of Life OCEAN study shows, article published in Haematologica	29.02.
Oncopeptides publishes year-end report 2023	27.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Oncopeptides AB

Aktien

A2DLU2

SE0009414576

ONCO

Andere Sprachen

Filter